治疗前MMP7预测抗纤维化治疗IPF患者的进展
本研究基于澳大利亚IPF注册库98例接受抗纤维化治疗的患者,在1年内四个时间点采集血清,检测10种生物标志物。结果显示基线MMP7水平在进展组高于稳定组,且能较好区分进展与稳定;MMP7升高预测12个月进展和总体死亡风险增加,多标志物组合及GAP联合标志物面板可提高预测准确性。
要点
- 基线MMP7水平可区分抗纤维化治疗IPF患者的进展与稳定。
- MMP7升高预测12个月进展和总体死亡风险增加。
- MMP7联合多标志物或GAP面板可提高对进展和死亡的预测。
核心结论
- MMP7联合多标志物面板及GAP面板可预测IPF进展和死亡,有望优化管理。
研究设计与样本
- 研究纳入澳大利亚IPF注册库98例接受抗纤维化治疗的IPF患者,分为两个队列分析。
- 抗纤维化治疗后1年内四个时间点采集血清,用ELISA检测10种目标分子。
- 进展定义为1年内FVC下降≥10%或DLCO下降≥15%或死亡,否则为稳定。
主要发现
- 队列1中进展组基线MMP7高于稳定组(p=0.02),队列2中亦高于稳定组(p=0.0002)。
- 基线MMP7区分进展与稳定的AUC在队列1为0.74(p=0.02),队列2为0.81(p=0.0003)。
- 合并队列回归分析显示,MMP7升高预测12个月进展(OR=1.530,p=0.010)和总体死亡风险增加(HR=1.268,p=0.002)。
- LASSO回归识别出MMP7、ICAM-1、CHI3L1、CA125多标志物面板,区分进展比MMP7单独更准确。
- GAP联合MMP7、ICAM-1、CCL18和SP-D对3年死亡的预测优于GAP单独。
临床怎么用
- 治疗前检测MMP7可能有助于识别抗纤维化治疗IPF患者中进展和死亡风险较高者。
- MMP7联合ICAM-1、CHI3L1、CA125或GAP面板可能提高风险分层准确性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Idiopathic pulmonary fibrosis (IPF) is a chronic progressive lung disease with a poor prognosis. Antifibrotics slow the decline of pulmonary function after 12-months, but limited studies have examined the role of circulatory biomarkers in antifibrotic treated IPF patients. METHODS: Serum from 98 IPF participants, from the Australian Idiopathic Pulmonary Fibrosis Registry were collected at four time-points over 1 year post-antifibrotic treatment and analysed as two separate cohorts. Patients were stratified as progressive, if they experienced ≥ 10% decline in FVC or ≥ 15% decline in DLCO or were deceased within 1 year of treatment initiation: or otherwise as stable. Ten molecules of interest were measured by ELISAs in patient serum. RESULTS: Baseline MMP7 levels were higher in progressive than stable patients in Cohort 1 (p = 0.02) and Cohort 2 (p = 0.0002). Baseline MMP7 levels also best differentiated progressive from stable patients (Cohort 1, AUC = 0.74, p = 0.02; Cohort 2, AUC = 0.81, p = 0.0003). Regression analysis of the combined cohort showed that elevated MMP7 levels predicted 12-month progression (OR = 1.530, p = 0.010) and increased risk of overall mortality (HR = 1.268, p = 0.002). LASSO regression identified a multi-biomarker panel (MMP7, ICAM-1, CHI3L1, CA125) that differentiated progression more accurately than MMP7 alone. Furthermore, GAP combined with MMP7, ICAM-1, CCL18 and SP-D was more predictive of 3-year mortality than GAP alone. CONCLUSION: MMP7 along with a multi-biomarker and GAP panel can predict IPF progression and mortality, with the potential for optimising management.
引用
- Li RM, Tan DBA, Tedja C, et al. Pre-Treatment MMP7 Predicts Progressive Idiopathic Pulmonary Fibrosis in Antifibrotic Treated Patients. Respirology. 2025. PMID: 39919729. doi:10.1111/resp.14894
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。